Shadi Haddadin, MD
Hematology & Oncology · Jefferson City, MONPI 1073611919
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 53 manufacturers, the largest accounting for just 14.3%. Among hematology & oncology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 294 payments — averaging $209.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharmacosmos Therapeutics Inc.$9K
- Jazz Pharmaceuticals Inc.$8K
- AstraZeneca$6K
- Sun Pharmaceutical Industries Inc.$5K
- AbbVie$4K
- Karyopharm Therapeutics Inc.$3K
- plus $28K from 47 others
Across 30 payments — averaging $2249.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$27K
- Beigene, Ltd.$22K
- Amgen$16K
- Pharmacyclics LLC, An Abbvie Company$3K
What the payments were for
- Consulting fees$34,53556%
- Speaking & faculty fees$16,86327%
- Travel & lodging$3,4506%
- Food & beverage$6,42310%
- Education$4211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monoferric$8,498
- ZEPZELCA$7,772
- YONSA$4,705
- Venclexta$3,463
- XPOVIO$2,690
- Stimufend$2,603
- DOPTELET$2,250
- BRUKINSA$2,250
- CALQUENCE$2,200
- PADCEV$1,992
- PGDx elio tissue complete$1,932
- BLENREP$1,925
- Luspatercept$1,796
- IMFINZI$1,110
- Oral Paclitaxel$800
- Encequidar$800
- Trodelvy$800
- Tepmetko$500
- Nubeqa$125
- PANZYGA$117
How this compares
$61,690 in reported general payments places this provider in the 95th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 51 | $846,453 |
| PomalystPomalidomide | 29 | $664,995 |
| RevlimidLenalidomide | 34 | $636,515 |
| TasignaNilotinib Hcl | 26 | $566,634 |
| ImbruvicaIbrutinib | 26 | $406,672 |
| BrukinsaZanubrutinib | 24 | $366,128 |
| IbrancePalbociclib | 18 | $273,635 |
| XtandiEnzalutamide | 17 | $239,817 |
| TagrissoOsimertinib Mesylate | 12 | $234,878 |
| NinlaroIxazomib Citrate | 13 | $191,963 |
| ErleadaApalutamide | 12 | $181,828 |
| Imatinib Mesylate | 74 | $172,345 |
| LynparzaOlaparib | 11 | $171,987 |
| VenclextaVenetoclax | 14 | $152,540 |
| PromactaEltrombopag Olamine | 20 | $151,769 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisTasigna, Promacta | $1,976 | $718,40346 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $451 | $664,99529 claims |
| Bristol Myers SquibbRevlimid | $2,181 | $636,51534 claims |
| AstraZenecaTagrisso, Lynparza | $5,888 | $406,86523 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $62 | $406,67226 claims |
| PfizerIbrance, Eliquis | $337 | $404,411202 claims |
| Beigene USA, Inc.Brukinsa | $2,303 | $366,12824 claims |
| Johnson & JohnsonErleada, Xarelto | $458 | $259,942109 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $42 | $191,96313 claims |
| AbbVieVenclexta, Creon | $3,809 | $168,98228 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $126 | $732118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in Jefferson City
- Ali KhojastehJefferson City$8K
- Tamara HopkinsJefferson City$6K
- David SchlossmanColumbia$1.2M
- Mark FeslerSaint Louis$870K
- Kelly PendergrassLees Summit$189K
- Jonathan MizrahiSaint Louis$188K
- Shahzad RazaKansas City$123K
- Stephanie GraffKansas City$105K
- Muhammad MirzaWashington$65K
- Yifan TuSt. Louis$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.